Precision of IMED-4 Lung Fluid Measurements

NCT ID: NCT02187770

Last Updated: 2015-10-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if IMED-4 recordings have sufficient precision to detect a clinically significant change in lung fluid status in acute heart failure syndrome with pulmonary congestion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will evaluate if the IMED-4 system has the precision to detect a clinically significant change in lung fluid status for patients with confirmed acute heart failure syndrome with pulmonary congestion. Changes in lung fluid in acute heart failure syndrome are difficult to diagnose and evaluate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyspnea Acute Heart Failure Syndrome Pulmonary Congestion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IMED-4

Non invasive recording electrode used to assess lung fluid

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosed with acute heart failure syndrome with pulmonary congestion defined by a Brain natriuretic peptide (BNP) \>350 pg/mL or N-terminal pro-brain natriuretic peptide (NT-pro BNP) \>1500 pg/mL and any one of the following:

1. PCWP \>25mmHg
2. Dyspnea at rest in a recumbent sitting position (30 to 45 degrees), which has worsened within the past week
3. Radiological evidence of CHF on a chest X-ray
4. Physical exam as evidence for pulmonary congestion:

i. Presence of an S3 heart sound ii. Lung rales/crackles/crepitations
2. Age greater than or equal to (≥) 18
3. Ability to reliably carry out self-assessment of symptoms
4. Willingness, ability and commitment to participate in index and follow-up IMED-4 recordings

Exclusion Criteria

1. Known active myocarditis, obstructive hypertrophic cardiomyopathy, constrictive pericarditis, uncorrected clinically significant primary valvular disease
2. Clinical diagnosis of acute coronary syndrome meeting any 2 of the following 3 criteria:

1. Prolonged chest pain at rest, or an accelerated pattern of angina
2. Electrocardiogram changes indicative of ischemia or myocardial injury
3. Serum troponin \>3 times upper limit of lab normal
3. Clinically-suspected acute mechanical cause of ADHF (e.g., papillary muscular rupture); the diagnosis need not be confirmed by imaging or cardiac catheterization
4. Estimated Glomerular Filtration Rate: eGFR \<30mL/min/1.73m
5. Known vasculitis, active infective endocarditis, or suspected infections including pneumonia, acute hepatitis, systemic inflammatory response syndrome, or sepsis
6. Body temperature ≥38°C just prior to enrollment
7. Acute or chronic respiratory disorder (e.g. severe chronic obstructive pulmonary disease (COPD)) or primary pulmonary hypertension sufficient to cause dyspnea at rest, which may interfere with the ability to interpret dyspnea assessments or hemodynamic measurements
8. Total Albumin \<2.5 g/dL
9. Patients requiring mechanical circulatory support
10. Pregnancy or lactation
11. Patients who have tattoos and/or non-intact skin directly under the electrode sensor position
12. Patients who have had past allergic reactions to medical grade adhesives
13. Patients who have had a lung lobectomy
14. Patients who decline to have their backs photographed with the IMED-4 device in position
15. Severe co-morbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, incarceration, shortened life expectance, etc.)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Intersection Medical, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mass General Hospital

Boston, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Ohio State University

Columbus, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP-000040

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.